Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 6, 2014, Pages 408-415

  Wang, Ying ^a,b   Li, Xiang Ping ^a,b   Yin, Ji Ye ^a   Zhang, Yu ^a   He, Hui ^a   Qian, Chen Yue ^a   Chen, Juan ^a   Zheng, Yi ^a   Smieszkol, Kamila ^a   Fu, Yi Lan ^a,c   Chen, Zi Yu ^a,c   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c HUNAN CANCER HOSPITAL   (China)

Author keywords

HMGB1; HMGB2; Lung cancer; Platinum based chemotherapy; Polymorphism

Indexed keywords

CARBOPLATIN; CISPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; ANTINEOPLASTIC AGENT; GENETIC MARKER; HMGB1 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CHINESE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; FEMALE; GENETIC MARKERS; GENOTYPE; HMGB1 PROTEIN; HMGB2 PROTEIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 84901239217     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12232     Document Type: Article

References (61)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2011; 63: 11-30.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N. Engl. J. Med. 2004; 350: 379-92.
4. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007; 59: 696-9.
5. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007; 7: 573-84.
6. Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance. Still searching for the Achilles' heel. Drug Resist. Updat. 2004; 7: 227-32.
7. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 2007; 63: 12-31.
8. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther. 2005; 107: 155-76.
9. Yin JY, Huang Q, Yang Y et al. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet. Genomics 2009; 19: 206-16.
10. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One 2012; 7: e38150.
11. Xu X, Ren H, Zhou B et al. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2012; 77: 438-42.
12. Xu X, Han L, Yang H et al. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients. Lung Cancer 2013; 79: 65-72.
13. Xu X, Duan L, Zhou B et al. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin. Exp. Pharmacol. Physiol. 2012; 39: 786-92.
14. Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 2006; 24: 2237-44.
15. Tibaldi C, Giovannetti E, Vasile E et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 2008; 14: 1797-803.
16. Kalikaki A, Kanaki M, Vassalou H et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 2009; 10: 118-23.
17. Shiraishi K, Kohno T, Tanai C et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 2010; 28: 4945-52.
18. Kang R, Zhang Q, Zeh HJ, Lotze MT III, Tang D. HMGB1 in cancer: Good, bad, or both? Clin. Cancer Res. 2013; 19: 4046-57.
19. Arioka H, Nishio K, Ishida T et al. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells. Jpn. J. Cancer Res. 1999; 90: 108-15.
20. Tang D, Kang R, Zeh HJ, Lotze MT III. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 2010; 1799: 131-40.
21. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1, RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010; 28: 367-88.
22. Lange SS, Vasquez KM. HMGB1: The jack-of-all-trades protein is a master DNA repair mechanic. Mol. Carcinog. 2009; 48: 571-80.
23. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 1994; 269: 787-90.
24. Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY. Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol. Cancer Ther. 2009; 8: 864-72.
25. Suzuki Y, Mimura K, Yoshimoto Y et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012; 72: 3967-76.
26. Yoav B, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1995; 57: 289-300.
27. Ueda T, Yoshida M. HMGB proteins and transcriptional regulation. Biochim. Biophys. Acta 2012; 1799: 114-8.
28. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J. Endotoxin Res. 2001; 7: 315-21.
29. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005; 5: 331-42.
30. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 2011; 29: 139-62.
31. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am. J. Pathol. 1999; 155: 1985-92.
32. Jayaraman L, Moorthy NC, Murthy KG et al. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 1998; 12: 462-72.
33. McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell. Biol. 2002; 22: 6797-808.
34. Livesey KM, Tang D, Zeh HJ, Lotze MT. Not just nuclear proteins. 'Novel' autophagy cancer treatment targets -p53 and HMGB1. Curr. Opin. Investig. Drugs 2008; 9: 1259-63.
35. Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem. 2002; 277: 7157-64.
36. Brickman JM, Adam M, Ptashne M. Interactions between an HMG-1 protein and members of the Rel family. Proc. Natl Acad. Sci. USA 1999; 96: 679-83.
37. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol. Sin. 2007; 28: 1957-67.
38. El Marzouk S, Gahattamaneni R, Joshi SR, Scovell WM. The plasticity of estrogen receptor-DNA complexes: Binding affinity and specificity of estrogen receptors to estrogen response element half-sites separated by variant spacers. J. Steroid Biochem. Mol. Biol. 2008; 110: 186-95.
39. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005; 26: 293-301.
40. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs 2003; 4: 1405-9.
41. Vaisman A, Lim SE, Patrick SM et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 1999; 38: 11026-39.
42. Kornblit B, Munthe-Fog L, Petersen SL et al. The genetic variation of the human HMGB1 gene. Tissue Antigens 2007; 70: 151-6.
43. Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: New fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995; 23: 4878-84.
44. Lum HK, Lee KL. The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron. Biochim. Biophys. Acta 2001; 1520: 79-84.
45. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res. 1998; 26: 1135-43.
46. Mailly F, Berube G, Harada R et al. The human cut homeodomain protein can repress gene expression by two distinct mechanisms: Active repression and competition for binding site occupancy. Mol. Cell. Biol. 1996; 16: 5346-57.
47. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature 1988; 335: 835-7.
48. Hernandez-Munain C, Krangel MS. Regulation of the T-cell receptor delta enhancer by functional cooperation between c-Myb and core-binding factors. Mol. Cell. Biol. 1994; 14: 473-83.
49. Chayka O, Kintscher J, Braas D, Klempnauer KH. v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter. Mol. Cell. Biol. 2005; 25: 499-511.
50. Duan ZX, Zhu PF, Dong H et al. Functional significance of the TLR4/11367 polymorphism identified in Chinese Han population. Shock 2007; 28: 160-4.
51. Kornblit B, Masmas T, Petersen SL et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2010; 16: 239-52.
52. Zeng L, Zhang AQ, Gu W et al. Clinical relevance of single nucleotide polymorphisms of the high mobility group box 1 protein gene in patients with major trauma in southwest China. Surgery 2012; 151: 427-36.
53. Deng CQ, Deng GH, Wang YM. HMGB1 gene polymorphisms in patients with chronic hepatitis B virus infection. World J. Gastroenterol. 2013; 19: 5144-9.
54. Kornblit B, Munthe-Fog L, Madsen HO et al. Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome. Crit. Care 2008; 12: R83.
55. Shang GH, Jia CQ, Tian H et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir. Med. 2009; 103: 1949-53.
56. Naumnik W, Nilklinska W, Ossolinska M, Chyczewska E. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem. Cytobiol. 2009; 47: 703-9.
57. Rosti G, Bevilacqua G, Bidoli P et al. Small cell lung cancer. Ann. Oncol. 2006; 17: 5-10.
58. Watanabe H, Okada M, Kaji Y et al. New response evaluation criteria in solid tumours: Revised RECIST guideline version 1.1. Gan To Kagaku Ryoho 2009; 36: 2495-501 (in Japanese).
59. Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52-8.
60. International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-96.
61. Micke P, Faldum A, Metz T et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: What limits limited disease? Lung Cancer 2002; 37: 271-6.